ArticleReviews in cardiovascular medicine2025
Body Surface Area-Weighted Left Ventricular Ejection Fraction Enhances Prediction Accuracy of OPCABG Outcomes: A Large Multi-Center Cohort Study.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02400125 (China Cardiovascular Surgery Registry), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
China Cardiovascular Surgery Registry
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We hypothesized that body surface area (BSA)-weighted left ventricular ejection fraction (LVEF) (bLVEF) would represent a superior predictor of mortality in off-pump coronary artery bypass grafting (OPCABG) patients than standard predictors. LVEF is associated with worse outcomes upon OPCABG, while referring left ventricular measurements to BSA should improve predictability. Methods: The bLVEF was calculated by multiplying the LVEF by the BSA. The primary endpoint was all-cause mortality within 30 days of hospitalization, while secondary endpoints included major postoperative complications. Results: A total of 7927 patients from five leading cardiac centers participating in the Chinese Cardiac Surgery Registry were included in the final analysis, of which 7093 (89.48%) had normal LVEF, 639 (8.06%) presented heart failure with mid-range ejection fraction (HFmrEF), and 195 (2.46%) exhibited heart failure with reduced ejection fraction (HFrEF). The average bLVEF in the cohort was 109.63 ± 18.16. Both the mortality (odds ratio (OR) 0.97) and secondary endpoints (OR 0.97) followed a similar trend with increasing bLVEF, indicating that bLVEF is a more reliable predictor of adverse outcomes. The individual components of bLVEF, including BSA (area under the curve (AUC) 0.63) and LVEF (AUC 0.64), made minor contributions to mortality risk with relatively low AUC values. However, these components were less impactful than bLVEF (AUC 0.70). Notably, patients with a bLVEF less than 85 had an increased mortality risk relative to those whose bLVEF was 85 or higher (adjusted OR 4.65 (95% confidence interval (CI): 3.81-5.83; Conclusion: The bLVEF serves as a key predictor of mortality in OPCABG patients, effectively eliminating BSA-related bias and demonstrating a strong capacity to predict mortality. Clinical Trial Registration: NCT02400125, https://www.clinicaltrials.gov/study/NCT02400125.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.